EVO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 02:58):

Stats
今日成交量	728 323
平均成交量	99 736.00
市值	1.90B
EPS	$-0.120 ( 2023-11-08 )
下一个收益日期	( $-0.100 ) 2024-06-10
Last Dividend	$0.0722 ( 2019-01-11 )
Next Dividend	$0 ( N/A )
P/E	-21.40
ATR14	$0.0100 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2018-10-22	Anderson Mark Monroe	Buy	100 000	Stock Option (right to buy)
2018-10-22	Anderson Mark Monroe	Buy	0
2018-08-13	Smith Scott Clifford	Buy	100 000	Stock Option (right to buy)
2018-08-13	Smith Scott Clifford	Buy	0
2018-08-13	Laffer Arthur B	Buy	100 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 13 transactions
Buy: 500 392 \| Sell: 1 057

音量相关性

長: -0.08 (neutral)

短: 0.31 (neutral)

Signal:(59.666) Neutral

Eaton Vance Ohio 相关性

10 最正相关
SOJD	0.872
RYB	0.869
WPM	0.869
NEU	0.869
KBH	0.867
SAP	0.851
GLDM	0.85
SGOL	0.85
OUNZ	0.849
BAR	0.849

10 最负相关
DZZ	-0.856
EQNR	-0.84
GLL	-0.836
DGZ	-0.835
EBF	-0.829
DBMF	-0.817
RPM	-0.814
PKO	-0.814
PCQ	-0.814
KMLM	-0.809

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Eaton Vance Ohio 相关性 - 货币/商品

0.68
( moderate )

0.62
( weak )

0.00
( neutral )

0.67
( moderate )

0.21
( neutral )

-0.80
( strong negative )

Eaton Vance Ohio 财务报表

Annual	2023
营收:	$781.43M
毛利润:	$175.05M (22.40 %)
EPS:	$-0.470

FY	2023
营收:	$781.43M
毛利润:	$175.05M (22.40 %)
EPS:	$-0.470

FY	2022
营收:	$751.45M
毛利润:	$174.07M (23.16 %)
EPS:	$-0.990

FY	2021
营收:	$618.03M
毛利润:	$151.54M (24.52 %)
EPS:	$0.650

Financial Reports:

No articles found.

Eaton Vance Ohio Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Eaton Vance Ohio Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 3.29 - low (9.42%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0561	2001-01-05
Last Dividend	$0.0722	2019-01-11
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	221	--
Total Paid Out	$14.33	--
Avg. Dividend % Per Year	0.00%	--
Score	3.4	--
Div. Sustainability Score	3.29
Div.Growth Potential Score	0
Div. Directional Score	1.328	--

Next Divdend (Est)
(2024-06-25)

$0 Estimate 0.00 %

Dividend Stability

0.16 Bad

Dividend Score

3.40

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$1.008	24.50%
2005	$1.024	55.70%
2006	$0.704	34.50%
2007	$0.650	153.20%
2008	$0.738	177.80%
2009	$0.814	150.70%
2010	$0.966	61.90%
2011	$0.857	41.40%
2012	$0.832	54.40%
2013	$0.793	45.30%
2014	$0.732	28.90%
2015	$0.732	32.70%
2016	$0.570	25.20%
2017	$0.576	14.20%
2018	$0.495	6.05%
2019	$0.0722	0.71%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.111	1.500	-2.22	-3.33	[0 - 0.5]
returnOnAssetsTTM	-0.0367	1.200	-1.224	-1.469	[0 - 0.3]
returnOnEquityTTM	-0.0731	1.500	-1.923	-2.88	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.944	0.800	5.28	4.22	[1 - 3]
quickRatioTTM	1.740	0.800	4.47	3.58	[0.8 - 2.5]
cashRatioTTM	1.100	1.500	5.00	7.50	[0.2 - 2]
debtRatioTTM	0.272	-1.500	5.46	-8.19	[0 - 0.6]
interestCoverageTTM	-6.79	1.000	-3.63	-3.63	[3 - 30]
operatingCashFlowPerShareTTM	0.192	2.00	9.94	10.00	[0 - 30]
freeCashFlowPerShareTTM	-1.029	2.00	-0.514	-1.029	[0 - 20]
debtEquityRatioTTM	0.559	-1.500	7.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.226	1.000	9.57	9.57	[0.2 - 0.8]
operatingProfitMarginTTM	-0.0826	1.000	-3.65	-3.65	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0542	1.000	-0.810	-0.810	[0.2 - 2]
assetTurnoverTTM	0.330	0.800	-1.130	-0.904	[0.5 - 2]
Total Score				3.29

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-10.27	1.000	-1.138	0	[1 - 100]
returnOnEquityTTM	-0.0731	2.50	-1.236	-2.88	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.029	2.00	-0.343	-1.029	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.192	2.00	9.94	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.488	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0447	1.000	-1.383	0	[0.1 - 0.5]
Total Score				-0.630

Eaton Vance Ohio

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.